person · Reporting owner

Clancy Paul J

Disclosed activity across 7 companies

Tapewire entity: 33396
SEC CIK: 0001409601

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499	Director	June 21, 2022	June 23, 2022
ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086	EVP, Chief Financial Officer	July 11, 2019	July 15, 2019
BIOGEN INC.BIIB · Entity 1675	Executive VP and CFO	April 25, 2017	April 27, 2017
INCYTE CORPINCY · Entity 3182	Director	September 30, 2026	October 03, 2026
Sionna Therapeutics, Inc.SION · Entity 5996	Director	June 17, 2026	June 18, 2026
Xilio Therapeutics, Inc.XLO · Entity 7122	Director	June 11, 2025	June 12, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date June 21, 2022 · Filed June 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted stock unitSEC Table II · derivative / convertible security	Direct	4,975	Reported balance After 2022-06-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-21 · Grant · Acquired 4,975 · Balance 4,975 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.09 · Expires 2032-06-21	Direct	29,307	Reported balance After 2022-06-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-21 · Grant · Acquired 29,307 · Balance 29,307 F3: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023.

ALEXION PHARMACEUTICALS, INC.

Report date July 11, 2019 · Filed July 15, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	90,447	Reported balance After 2019-07-11 transaction · row 1 1 source row Row 1 · 2019-07-11 · Tax withholding · Disposed 5,230 · Balance 90,447 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.

BIOGEN INC.

Report date April 25, 2017 · Filed April 27, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,813	Reported balance After 2017-04-25 transaction · row 1 1 source row Row 1 · 2017-04-25 · Sale · Disposed 9,892 · Balance 10,813 F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

Filing footnotes · ownership attribution and instrument terms

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

INCYTE CORP

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,838	Reported balance After 2026-09-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 203 · Balance 25,838 F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Sionna Therapeutics, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.73 · Expires 2036-06-16	Direct	17,340	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 17,340 · Balance 17,340 F1: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

Xilio Therapeutics, Inc.

Report date June 11, 2025 · Filed June 12, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2035-06-10	Direct	31,000	Reported balance After 2025-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-11 · Grant · Acquired 31,000 · Balance 31,000 F1: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EXACT SCIENCES CORP

Report date March 23, 2026 · Filed March 23, 2026

Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-03-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-23 · Disposition to issuer · Disposed 20,640 · Balance 5,398 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 5,398 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Filing footnotes · ownership attribution and instrument terms

F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 26, 2021 Filed Oct 26, 2021 21:01 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	65,528	$0.00 Strike: $5.89	$0.00	Disclosure SEC source: 0001104659-21-130022 · tm2130646-19_4seq1.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,528 Underlying: Common Stock · 65,528 shares Expires 2021-03-10 F2 · derivative.exercise_date: On March 11, 2021, the reporting person was granted an option to purchase 65,528 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's IPO. The Company's IPO closed as of October 26, 2021. On October 26, 2021, 20,477 shares underlying the option vested and the remainder will vest in equal monthly installments until July 16, 2024. Read SEC document
October 26, 2021 Filed Oct 26, 2021 21:01 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	44,033	$0.00 Strike: $5.51	$0.00	Disclosure SEC source: 0001104659-21-130022 · tm2130646-19_4seq1.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,033 Underlying: Common Stock · 44,033 shares Expires 2030-07-22 F1 · derivative.exercise_date: On July 23, 2020, the reporting person was granted an option to purchase 44,033 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's initial public offering ("IPO"). The Company's IPO closed as of October 26, 2021. On October 26, 2021, 13,760 shares underlying the award vested and the remainder will vest in equal monthly installments until July 16, 2024. Read SEC document
September 30, 2021 Filed Oct 4, 2021 20:26 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	321	$68.78	$22,078.38	Disclosure SEC source: 0001209191-21-058958 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,621 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 30, 2021 Filed Jul 2, 2021 11:16 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	283	$84.13	$23,808.79	Disclosure SEC source: 0001209191-21-044642 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 30, 2021 Filed Jul 2, 2021 16:06 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	2,567	$0.00	$0.00	Disclosure SEC source: 0001209191-21-044894 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,496 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document
May 28, 2021 Filed Jun 2, 2021 20:07 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	1,686	$0.00	$0.00	Disclosure SEC source: 0001439222-21-000052 · wf-form4_162266445283384.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document
May 28, 2021 Filed Jun 2, 2021 20:07 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	1,686	$0.00	$0.00	Disclosure SEC source: 0001439222-21-000052 · wf-form4_162266445283384.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 26, 2021 Filed May 28, 2021 11:01 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	8,010	$0.00 Strike: $83.16	$0.00	Disclosure SEC source: 0001209191-21-036401 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,010 Underlying: Common Stock · 8,010 shares Expires 2031-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
May 26, 2021 Filed May 28, 2021 11:01 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,923	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036401 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,017 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
May 20, 2021 Filed May 24, 2021 20:44 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	8,888	$0.00 Strike: $56.76	$0.00	Disclosure SEC source: 0001439222-21-000043 · wf-form4_162188904410902.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common stock · 8,888 shares Expires 2031-05-20 F3 · derivative.exercise_date: This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022. Read SEC document
May 20, 2021 Filed May 24, 2021 20:44 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock unit · Derivative	1,585	$0.00	$0.00	Disclosure SEC source: 0001439222-21-000043 · wf-form4_162188904410902.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585 Underlying: Common stock · 1,585 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document
March 31, 2021 Filed Apr 1, 2021 21:07 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	298	$81.27	$24,218.46	Disclosure SEC source: 0001209191-21-024152 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,094 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
March 18, 2021 Filed Mar 19, 2021 17:05 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	2,929	$0.00	$0.00	Disclosure SEC source: 0001209191-21-022123 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,929 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
December 31, 2020 Filed Jan 5, 2021 21:55 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	281	$86.98	$24,441.38	Disclosure SEC source: 0001209191-21-001226 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,796 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
September 30, 2020 Filed Oct 1, 2020 20:43 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	260	$89.74	$23,332.40	Disclosure SEC source: 0001209191-20-052629 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,515 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 30, 2020 Filed Jul 1, 2020 20:51 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	229	$103.97	$23,809.13	Disclosure SEC source: 0001209191-20-039772 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,255 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
May 29, 2020 Filed Jun 1, 2020 21:14 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	1,878	$0.00	$0.00	Disclosure SEC source: 0001439222-20-000053 · wf-form4_159104602309461.xml · derivative · entry 4 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document
May 29, 2020 Filed Jun 1, 2020 21:14 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	1,878	Not disclosed	Not disclosed	Disclosure SEC source: 0001439222-20-000053 · wf-form4_159104602309461.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:14 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	1,686	$0.00	$0.00	Disclosure SEC source: 0001439222-20-000053 · wf-form4_159104602309461.xml · derivative · entry 3 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,686 Underlying: Common stock · 1,686 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:14 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	8,096	$0.00 Strike: $53.35	$0.00	Disclosure SEC source: 0001439222-20-000053 · wf-form4_159104602309461.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,096 Underlying: Common stock · 8,096 shares Expires 2030-05-28 F2 · derivative.exercise_date: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021. Read SEC document
May 26, 2020 Filed May 28, 2020 20:13 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,514	$0.00 Strike: $98.68	$0.00	Disclosure SEC source: 0001209191-20-032579 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,514 Underlying: Common Stock · 10,514 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
May 26, 2020 Filed May 28, 2020 20:13 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,282	$0.00	$0.00	Disclosure SEC source: 0001209191-20-032579 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,026 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
March 31, 2020 Filed Apr 2, 2020 21:04 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	287	$73.23	$21,017.01	Disclosure SEC source: 0001209191-20-022680 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,744 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:09 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	231	$87.32	$20,170.92	Disclosure SEC source: 0001209191-20-000810 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,457 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
September 30, 2019 Filed Oct 2, 2019 20:08 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	266	$74.23	$19,745.18	Disclosure SEC source: 0001209191-19-051625 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,226 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
July 11, 2019 Filed Jul 15, 2019 17:01 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	5,230	$124.20	$649,566.00	Disclosure SEC source: 0000899866-19-000080 · wf-form4_156322444530801.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,447 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
June 28, 2019 Filed Jul 2, 2019 20:31 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	237	$84.96	$20,135.52	Disclosure SEC source: 0001209191-19-040306 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
May 31, 2019 Filed May 31, 2019 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	1,400	$0.00	$0.00	Disclosure SEC source: 0001209191-19-033614 · doc4.xml · derivative · entry 4 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 31, 2019 Filed May 31, 2019 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	1,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-033614 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document
May 29, 2019 Filed May 31, 2019 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	1,878	$0.00	$0.00	Disclosure SEC source: 0001209191-19-033614 · doc4.xml · derivative · entry 3 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878 Underlying: Common stock · 1,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 29, 2019 Filed May 31, 2019 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	8,919	$0.00 Strike: $47.91	$0.00	Disclosure SEC source: 0001209191-19-033614 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,919 Underlying: Common stock · 8,919 shares Expires 2029-05-29 F2 · derivative.exercise_date: This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020. Read SEC document
April 26, 2019 Filed Apr 29, 2019 21:04 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	12,472	$0.00 Strike: $75.03	$0.00	Disclosure SEC source: 0001209191-19-026434 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 Underlying: Common Stock · 12,472 shares Expires 2029-04-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
April 26, 2019 Filed Apr 29, 2019 21:04 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,520	$0.00	$0.00	Disclosure SEC source: 0001209191-19-026434 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,723 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
March 29, 2019 Filed Apr 2, 2019 21:08 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	203	$86.01	$17,460.03	Disclosure SEC source: 0001209191-19-022646 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document
February 28, 2019 Filed Mar 4, 2019 17:37 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,079	$132.93	$143,431.47	Disclosure SEC source: 0000899866-19-000038 · wf-form4_155173906391052.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,249 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $135.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 28, 2019 Filed Mar 5, 2019 20:13 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	9,428	$0.00	$0.00	Disclosure SEC source: 0000899866-19-000045 · wf-form4_155183479037689.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,677 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
February 07, 2019 Filed Feb 11, 2019 18:21 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	5,981	$119.57	$715,148.17	Disclosure SEC source: 0000899866-19-000013 · wf-form4_154992729099866.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,328 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $119.45 - $119.57. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
July 10, 2018 Filed Jul 12, 2018 17:23 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	5,241	$131.11	$687,147.51	Disclosure SEC source: 0000899866-18-000114 · wf-form4_153143060154063.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,309 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	1,400	$0.00	$0.00	Disclosure SEC source: 0001209191-18-035022 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	5,700	$0.00 Strike: $93.50	$0.00	Disclosure SEC source: 0001209191-18-035022 · doc4.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document
May 01, 2018 Filed May 3, 2018 21:24 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Options (right to buy) · Derivative	15,000	$0.00 Strike: $60.85	$0.00	Disclosure SEC source: 0001209191-18-027732 · doc4.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:02 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	9,536	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000064 · wf-form4_152002814448586.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,550 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
February 08, 2018 Filed Feb 8, 2018 19:17 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	6,079	$116.31	$707,048.49	Disclosure SEC source: 0000899866-18-000040 · wf-form4_151813542168787.xml · nonDerivative · entry 2 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,014 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 06, 2018 Filed Feb 8, 2018 19:17 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	48,228	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000040 · wf-form4_151813542168787.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,093 F1 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 48,228 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. Read SEC document
July 10, 2017 Filed Jul 12, 2017 18:11 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantOption to Purchase Common Stock · Derivative	29,089	$0.00 Strike: $123.76	$0.00	Disclosure SEC source: 0000899866-17-000149 · wf-form4_149989747544708.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,089 Underlying: Common Stock, par value $.0001 per share · 29,089 shares Expires 2027-07-10 F2 · shares: Award of Stock Options under 2017 Incentive Plan. 25% vest on the one year anniversary of the grant date and 1/16th every 90 days thereafter. Read SEC document
July 10, 2017 Filed Jul 12, 2017 18:11 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	46,865	$0.00	$0.00	Disclosure SEC source: 0000899866-17-000149 · wf-form4_149989747544708.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,865 F1 · shares: Award of Restricted Stock Units under 2017 Incentive Plan. 25% vest on each anniversary of the grant date. Read SEC document
June 13, 2017 Filed Jun 15, 2017 21:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	9,000	$0.00 Strike: $50.73	$0.00	Disclosure SEC source: 0001209191-17-040188 · doc4.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 9,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018. Read SEC document
May 26, 2017 Filed May 31, 2017 20:26 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Options (right to buy) · Derivative	15,000	$0.00 Strike: $134.38	$0.00	Disclosure SEC source: 0001209191-17-036443 · doc4.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document
April 25, 2017 Filed Apr 27, 2017 20:23 UTC	BIOGEN INC. BIIB · Entity 1675	SaleCommon Stock	9,892	$290.00	$2,868,680.00	Disclosure SEC source: 0001127602-17-015712 · form4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,813 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document
March 13, 2017 Filed Mar 14, 2017 23:32 UTC	BIOGEN INC. BIIB · Entity 1675	SaleCommon Stock	9,891	$291.55	$2,883,721.05	Disclosure SEC source: 0001127602-17-011701 · form4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,705 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.